Varaico: Literature-Extracted Genetic Variants

Gene:RAD51C
Variant:p.R168*
Back to variants list

RAD51C

NM_058216.3:p.R168*

Associated Papers

Risk of lymphoid malignancy associated with cancer predisposition genes.

Boddicker NJ et al.

Blood Cancer Journal, 2025

40253392 (PubMed )
Supplement: 41408_2025_1283_MOESM1_ESM.xlsx › Table_S15

Pathogenic variants in human DNA damage repair genes mostly arose after the latest human out-of-Africa migration.

He J et al.

Frontiers in Genetics, 2024

38948361 (PubMed )
Supplement: Table1.XLSX › Sheet1

Hereditary cancer predispositions: Comparison of multigene panel sequencing on fresh-frozen breast/ovarian tumor versus blood.

Schwartz M et al.

Clinical Genetics, 2023

Germline multigene panel testing of patients with endometrial cancer.

Kral J et al.

Oncology Letters, 2023

37153042 (PubMed )
Supplement: Supplementary_Data.pdf

Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.

Hlaváč V et al.

Life Science Alliance, 2022

36229065 (PubMed )
Supplement: LSA-2022-01551_TableS15.xlsx › Table_S15

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor.

Ogrodniczak A et al.

Hereditary Cancer in Clinical Practice, 2022

Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development.

Kondrashova O et al.

Cancers, 2021

33917078 (PubMed )
Supplement: cancers-13-01762-s001.zip › Kondrashova_etal_Supp_Tables.xlsx › Table_S5

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.

Yang X et al.

Journal of the National Cancer Institute, 2020

32107557 (PubMed )
Supplement: djaa030_supplementary_data.pdf

Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.

Soukupova J et al.

Plos One, 2018

29649263 (PubMed )
Supplement: pone.0195761.s006.xlsx › S6

Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients.

Lhota F et al.

Clinical Genetics, 2016

RE: frameshift variant FANCL*c.1096_1099dupATTA is not associated with high breast cancer risk.

Zemankova P et al.

Clinical Genetics, 2016

Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.

Yablonski-Peretz T et al.

Breast Cancer Research and Treatment, 2016

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."